In a phase 2 trial, orelabrutinib plus sintilimab yielded a 60.7% overall response rate in relapsed/refractory primary CNS lymphoma.
|Articles|October 7, 2008
Hematological Malignancies: Current Perspectives on Diagnosis, Prognosis, and Treatment.
This supplement to ONCOLOGY provides a comprehensive look at state-of-the-art management of three of the most prevalent hematological malignancies in the US today.
Advertisement
This supplement to ONCOLOGY provides a comprehensive look at state-of-the-art management of three of the most prevalent hematological malignancies in the US today: chronic lymphocytic leukemia, non-Hodgkin lymphoma, and acute myeloid leukemia. This supplement is supported by an educational grant from Cephalon Oncology, and is jointly sponsored by Postgraduate Institute for Medicine and Vital Issues in Medicine. CME/PE/CE credit is available.
Advertisement
Related to this article
Oral vitamin C improved OS in patients with CCUS or lower-risk myeloid malignancies in the EVITA trial despite missing the clonal growth primary end point.
Advertisement
Advertisement
Trending on CancerNetwork
1
Blood mRNA Model Predicts Castration Resistance in Metastatic Prostate Cancer
2
Prioritizing Biomarker Testing to Conserve Tissue in Gastroesophageal Cancer
3
Choosing Between Triplet Therapy and Immunotherapy in BRAF-Mutant Melanoma
4
Triplet Therapy Emerges as a First-Line Option in BRAF V600–Mutant Melanoma
5